Literature DB >> 10086893

Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice.

E Verdú1, J J Vilches, F J Rodríguez, D Ceballos, A Valero, X Navarro.   

Abstract

We investigated the neuropathic effects of cisplatin in two groups of mice treated with 5 or 10 mg/kg/week of cisplatin for 7 or 8 weeks. Peripheral nerve functions were evaluated by sweat imprints, and electrophysiological, rotarod, and nociceptive tests. Protein gene product 9.5 (PGP), calcitonin gene-related peptide (CGRP), and vasoactive intestinal peptide (VIP) were immunohistochemically localized in footpads. Tibial nerves were analyzed morphometrically. Functional deficits developed progressively with higher cumulative doses, more markedly in mice treated with high than in those with low doses. From cumulative doses of 10 mg/kg, significant declines in sensory nerve conduction velocity and sudomotor responses were found, whereas motor and nociceptive functions were involved later. There were no morphometrical changes in tibial nerves. A marked decrease of CGRP- and VIP-immunoreactive nerves occurred in samples from treated mice, whereas PGP-labeled profiles decreased mildly at late stages. Impairment of the content of neuropeptides with neurosecretor role was detectable earlier than functional abnormalities. Immunohistochemical analysis of skin biopsies offers a useful diagnostic tool for peripheral neuropathies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086893     DOI: 10.1002/(sici)1097-4598(199903)22:3<329::aid-mus5>3.0.co;2-8

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  25 in total

1.  Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.

Authors:  Iryna A Khasabova; Sergey Khasabov; Justin Paz; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

2.  Amelioration of cisplatin-induced experimental peripheral neuropathy by a small molecule targeting p75 NTR.

Authors:  Amy Friesland; Zhiying Weng; Maria Duenas; Stephen M Massa; Frank M Longo; Qun Lu
Journal:  Neurotoxicology       Date:  2014-09-30       Impact factor: 4.294

3.  Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer.

Authors:  Óscar Arrieta; N Hernández-Pedro; M C Fernández-González-Aragón; D Saavedra-Pérez; A D Campos-Parra; M Á Ríos-Trejo; T Cerón-Lizárraga; L Martínez-Barrera; B Pineda; G Ordóñez; A Ortiz-Plata; V Granados-Soto; J Sotelo
Journal:  Neurology       Date:  2011-08-24       Impact factor: 9.910

4.  Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1.

Authors:  Yi-Chen Lee; Shui-Chin Lu; Yu-Lin Hsieh
Journal:  J Vis Exp       Date:  2018-02-13       Impact factor: 1.355

5.  Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept.

Authors:  Hue Jung Park; Jennifer A Stokes; Elaine Pirie; James Skahen; Yuri Shtaerman; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-12-07       Impact factor: 5.108

Review 6.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

Review 7.  Animal models of chemotherapy-evoked painful peripheral neuropathies.

Authors:  Nicolas Authier; David Balayssac; Fabien Marchand; Bing Ling; Aude Zangarelli; Juliette Descoeur; François Coudore; Emmanuel Bourinet; Alain Eschalier
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

8.  Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy.

Authors:  Munmun Chattopadhyay; Marina Mata; David J Fink
Journal:  J Neurosci       Date:  2008-06-25       Impact factor: 6.167

9.  Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy.

Authors:  Anna Dzagnidze; Zaza Katsarava; Julia Makhalova; Bernd Liedert; Min-Suk Yoon; Holger Kaube; Volker Limmroth; Juergen Thomale
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

Review 10.  Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy.

Authors:  Jordi Bruna; Paola Alberti; Aina Calls-Cobos; Martial Caillaud; M Imad Damaj; Xavier Navarro
Journal:  Exp Neurol       Date:  2019-12-15       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.